GlobeNewswire

Reselling Microsoft 365: New Opportunities with Microsoft's Visionary New Platform, AppRiver says

Dela

 

 

NOTE: The following article contains content from AppRiver. AppRiver could soon become even  more interesting for Swiss managed service providers. As AppRiver, in the next few weeks,  is very likely to be the first provider in Switzerland with Microsoft 365 on the market.

GULF BREEZE, Fla., May 17, 2018 (GLOBE NEWSWIRE) -- Microsoft 365 represents the fulfillment of Microsoft's longstanding vision to deliver an innovative portfolio of productivity, collaboration and security tools that address the future of business. It is the culmination of Microsoft's innovation, technology and forward strategy, and it will revolutionize how business users work and how administrators manage their IT infrastructure.

Microsoft looked deep into its crystal ball and saw how the modern workplace was drastically transforming. The future is cloud-based. It's mobile. It's global and dispersed. It's not tied to a formal office. And it's not secure.

For managed service providers (MSPs), consultants and resellers, Microsoft 365 presents a collection of enhanced business opportunities that will not only help to sell subscriptions, but also to educate clients and support the new infrastructure.
                                                            
Partners will need to develop a fluent understanding of the features, benefits and shortcomings of Microsoft 365 before making client presentations or recommendations. While Microsoft has generously provided a great deal of information on Microsoft 365, it can be a significant task to sort through the available assets and determine which are applicable.

Begin developing your knowledge of Microsoft 365 by understanding:

  • What Microsoft 365 encompasses
  • Key security considerations
  • New service and business opportunities

Microsoft 365: What's "In the Box"?
Many assume that Microsoft 365 is a new branding approach for the popular Office 365 suite of solutions. It isn't. Even at its most basic, Microsoft 365 is the applications, management tools and the operating system combined as one. It's a union that, at a glance, may seem unwieldy. However, its complexity is designed to transform the workplace for the better.

For partners, their clients and IT professionals, it is valuable to think of Microsoft 365 as a practice, not a product. While Microsoft 365 will have a significant impact on business users, it will be an entire shift in how IT administrators manage technology and their users. In turn, partners also need to take a different approach when presenting Microsoft 365 to clients.

Securing Microsoft 365
Microsoft 365 radically changes the security footprint and foundation. With Microsoft 365, all the pieces are working in concert and receive structured updates that are compatible with the entire stack. Among the many enhancements, Microsoft recognized that security can't be effectively addressed at only the enterprise or IT level, since end-users can infect the network with the click of a bad link. Therefore, Microsoft intelligently moved security to the user level and partners need to educate their clients on how to use these new tools.

Microsoft 365 outperforms legacy operating systems with a secure, modern state that extracts the best of Microsoft's new security capabilities. Moreover, while Microsoft 365 offers a wide range of security enhancements above and beyond Office 365, it will still require additional protections and will demand heightened monitoring and maintenance.

Microsoft 365: The Channel Opportunity
Beyond the opportunity to sell new subscriptions to customers, Microsoft 365 provides channel partners with a new opportunity to deliver ongoing service and support, along with the necessary hardware and security software that will power the next-generation, secure enterprise.

From a financial perspective, Microsoft 365 carries a higher perceived price point than Office 365, so gross margins will likely increase if partners apply the same markup methodology. Partners should expect a 10 - 18 percent increase in earnings over typical managed services.

Since Microsoft 365 is still new and there is much confusion in the market, partners can expect to receive many questions from clients. Some clients will also raise objections about the move to Microsoft 365 by attempting to hang on to current or legacy operating systems as long as possible.

Based on Microsoft's impassioned approach and the widespread benefits that Microsoft 365 will deliver, the upgrade to Microsoft 365 is essentially inevitable. It's not about if, it's when since many end-of-life (EOL) events are already scheduled to occur by the end of 2020. And while Microsoft has been known to extend EOL deadlines in the past, the transitions to Microsoft 365 and reseller opportunities will happen soon.

Next Steps: Getting Started
The need to get up-to-speed quickly on Microsoft 365's intricacies cannot be overstated. Few have time to sort through the bulk of Microsoft materials and extract the most actionable items, so it's helpful to locate materials, podcasts and videos that act as an "interpreter" to help decipher Microsoft's marketing language and support documentation for you and your customers.

There are also complimentary courses to help partners learn and sell Microsoft 365, some of which result in a certification medallion - a key element of validation that IT decision-makers will seek when selecting expert Microsoft 365 resellers.

Develop your knowledge, then get ready for the new era of opportunities with selling and supporting Microsoft's visionary new platform to IT decision-makers.

-----------------------------------
About the Author
Scott Paul is the Senior Director of AppRiver's Microsoft Alliance. AppRiver was one of the Microsoft's original go-to-market partners for Office 365 and now has one of the most experienced Office 365 support teams in the business. The company also provides free Microsoft 365 training courses for channel partners.
                                                       

CONTACT INFORMATION:

Jordi Vilanova
AppRiver
jvilanova@appriver.com
34-932-200-101 Ext 1002




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AppRiver via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum